Reduction of proteinuria by angiotensin converting enzyme (ACE) inhibitors has been described in primary renal diseases,' diabetes mellitus,2 and other secondary renal diseases such as lupus nephritis, Wegener's granulomatosis, etc. 3 There have only been a few reports of such treatment in patients with lupus nephritis and proteinuria.4 5 Experience with ACE inhibitors in severe nephrotic syndrome is limited. We report a case of lupus nephritis and intractable nephrotic syndrome in which captopril treatment resulted in a reduction in proteinuria and a substantial improvement of generalised oedema. Her haemoglobin concentration was 91 g/l. Creatinine 250 ,umolll, blood urea nitrogen 13-3 mmol/l, total protein 44 g/l, albumin 18 g/l, calcium 1-6 mmol/l, phosphorus 3-1 mmol/l, cholesterol 6-34 mmol/l. The blood picture was otherwise normal. Analysis of the urine showed a proteinuria of 28 g/24 hours and a few hyaline casts. Antinuclear factor was 1/80; anti-DNA 16-6% (normal <20%), C3 620 mg/l (normal 700-1760 mg/l), C4 420 mg/l (normal 160-450 mg/l). Lupus erythematosus cells were observed.
Chest x ray picture showed mild cardiomegaly and moderate pleural effusions. An abdominal ultrasound scan showed ascites and swollen kidneys-11 cm each. There were no signs of renal vein thrombosis. Renal biopsy was considered too risky because of the oedema and was therefore deferred.
The figure summarises the changes in body weight, proteinuria, and serum creatinine concentrations during the 12 weeks as an inpatient, and the drugs given during that period. Additional treatment comprised nifedipine 40 mg a day and prednisone 10 mg a day. It is evident that two weeks of treatment with salt free albumin and intravenous furosemide in doses up to 500 mg a day had no effect on body weight.
Thirteen days after admission captopril was given, starting with 18-75 mg a day and increasing to 62-5 mg a day after four days. She received that dose for 10 more weeks. Intravenous furosemide 300-400 mg a day in continuous drip over 12 hours was given until the seventh hospital week and then stopped. Atenolol was discontinued after five weeks. The patient lost 16 kg, of which 6-5 kg was lost during the 35 days of concurrent treatment with furosemide and the other 9-5 kg subsequently.
There was a considerable reduction in the anasarca, leaving only leg oedema.
Urinary protein excretion decreased from 28 g/24 hours at admission to 7'5, 13-2, and 11i5 g/24 hours in the sixth, eighth, and twelth week, respectively. Serum albumin concentrations rose from 18 g/l to 25-26 g/l. Blood pressure did not change during treatment and was usually about 170/100 mmHg. Serum creatinine concentration rose to 328-381 ,umol/I during the fourth hospital week after a febrile illness, returned to baseline concentrations of iimol/l, and rose again in the ninth week to about 355 imol/l. Creatinine clearance was 10 ml/minute on admission, and 8 ml/ minute after 12 weeks.
Once the oedema had begun to reduce a kidney biopsy specimen was taken, during the ninth week; this showed diffuse proliferative glomerulonephritis. By this time the patient had given her approval for cyclophosphamide pulses, which were begun in the thirteenth week of her stay. Two weeks later the serum creatinine concentration had fallen to 239 ,umol/l, albumin 28 gIl, creatinine clearance 13-8 ml/minute, and urinary protein excretion was 10-8 g/24 hours. Body weight further decreased to 46 kg. After the second pulse, the creatinine concentration decreased to 168 ,umol/l. 
